Prosecution Insights
Last updated: April 19, 2026
Application No. 17/773,895

METHOD FOR ISOLATING NUCLEIC ACIDS

Final Rejection §112
Filed
May 03, 2022
Examiner
HORLICK, KENNETH R
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nasasbiotech S L
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
2y 6m
To Grant
94%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
817 granted / 1035 resolved
+18.9% vs TC avg
Strong +15% interview lift
Without
With
+15.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
24 currently pending
Career history
1059
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
38.4%
-1.6% vs TC avg
§102
6.5%
-33.5% vs TC avg
§112
15.2%
-24.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1035 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . MAINTAINED REJECTION 2. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 25 and 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 25-26 are indefinite because it cannot be determined what is encompassed by a reagent ‘capable of isolating nucleic acids from EVs’, as a reagent cannot isolate nucleic acids, but can be used to isolate them. This language is not defined in the specification, and one of ordinary skill in the art would not be apprised of its meaning. Clarification is required. REPLY TO ARGUMENTS 3. With respect to the above rejection, the arguments of the response filed 01/09/26 on page 6 have been fully considered, but are not found persuasive. While the response argues that ‘reagent capable of isolating nucleic acids from EVs’ is expressly defined in the specification at the top of page 21, the Office does not agree. What is recited is ‘relates to any reagent to isolate nucleic acids associated to or inside the EVs’, which is not a definition, but merely an ‘intended use’ which does not define the reagent either structurally or functionally. While the response points to examples of what is intended by such a reagent, such examples or preferred embodiments are not to be read into claims. Clarification is required. ALLOWABLE SUBJECT MATTER 4. Claims 16-24 and 27 are allowable. Claims 25-26 are free of the prior art, but they are rejected for another reason. The arguments of the response on pages 6-9 regarding the obviousness rejection have been fully considered, and are persuasive to obviate the rejection, which is withdrawn. CONCLUSION 5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KENNETH R HORLICK whose telephone number is (571)272-0784. The examiner can normally be reached Mon. - Thurs. 8:30 - 6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. 03/09/26 /KENNETH R HORLICK/ Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

May 03, 2022
Application Filed
Jul 07, 2025
Non-Final Rejection — §112
Jan 09, 2026
Response Filed
Mar 09, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584159
SEPARATION OF NUCLEIC ACID COMPONENT COMPOUNDS ON ZWITTERIONIC STATIONARY PHASES
2y 5m to grant Granted Mar 24, 2026
Patent 12577613
SYSTEMS AND METHODS FOR SELECTIVE DNA MULTIPLE DISPLACEMENT AMPLIFICATION OF A DNA MIXTURE;
2y 5m to grant Granted Mar 17, 2026
Patent 12576399
DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES
2y 5m to grant Granted Mar 17, 2026
Patent 12571048
FRET-BASED ANALYTES DETECTION AND RELATED METHODS AND SYSTEMS
2y 5m to grant Granted Mar 10, 2026
Patent 12565674
METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
94%
With Interview (+15.1%)
2y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 1035 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month